Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 299

1.

Clinical Features, Pathogenesis, and Treatment of Large Granular Lymphocyte Leukemias.

Oshimi K.

Intern Med. 2017;56(14):1759-1769. doi: 10.2169/internalmedicine.56.8881. Epub 2017 Jul 15.

PMID:
28717070
2.

Evaluation of care for leukemia and lymphoma patients during their last hospitalization from the perspective of the bereaved family.

Shirai Y, Miyashita M, Kawa M, Motokura T, Sano F, Fukuda T, Oshimi K, Kazuma K.

Leuk Res. 2016 Aug;47:93-9. doi: 10.1016/j.leukres.2016.05.016. Epub 2016 May 25.

PMID:
27289478
3.

Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group.

Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, Tsurumi H, Nakao S, Urabe A, Fujisawa S, Yonemura Y, Kawano F, Oshimi K, Sugimoto K, Matsuda A, Karasawa M, Arai A, Komatsu N, Harigae H, Omine M, Ozawa K, Kurokawa M; PRCA Collaborative Study Group.

Br J Haematol. 2015 Jun;169(6):879-86. doi: 10.1111/bjh.13376. Epub 2015 Mar 25.

PMID:
25807974
4.

Prognostic biomarkers in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.

Yamaguchi M, Takata K, Yoshino T, Ishizuka N, Oguchi M, Kobayashi Y, Isobe Y, Ishizawa K, Kubota N, Itoh K, Usui N, Miyazaki K, Wasada I, Nakamura S, Matsuno Y, Oshimi K, Kinoshita T, Tsukasaki K, Tobinai K.

Cancer Sci. 2014 Nov;105(11):1435-41. doi: 10.1111/cas.12526. Epub 2014 Oct 4.

5.

Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: an updated analysis of the Japan clinical oncology group study JCOG0211.

Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, Ishizawa K, Maseki N, Itoh K, Usui N, Wasada I, Kinoshita T, Hotta T, Tsukasaki K, Oshimi K.

J Clin Oncol. 2012 Nov 10;30(32):4044-6. doi: 10.1200/JCO.2012.45.6541. Epub 2012 Oct 8. No abstract available.

PMID:
23045573
6.

Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.

Ito Y, Kimura H, Maeda Y, Hashimoto C, Ishida F, Izutsu K, Fukushima N, Isobe Y, Takizawa J, Hasegawa Y, Kobayashi H, Okamura S, Kobayashi H, Yamaguchi M, Suzumiya J, Hyo R, Nakamura S, Kawa K, Oshimi K, Suzuki R.

Clin Cancer Res. 2012 Aug 1;18(15):4183-90. Epub 2012 Jun 6.

7.

Extranodal natural killer/T-cell lymphoma from skin or soft tissue: suggestion of treatment from multinational retrospective analysis.

Ahn HK, Suh C, Chuang SS, Suzumiya J, Ko YH, Kim SJ, Huh JR, Yoon DH, Oh SY, Kim JS, Lee SI, Park KW, Hsieh PP, Nakamura S, Yoshino T, Ito K, Nagatani T, Oshimi K, Suzuki R, Kim WS.

Ann Oncol. 2012 Oct;23(10):2703-7. Epub 2012 Apr 29.

PMID:
22547542
8.

Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation.

Ishida F, Ko YH, Kim WS, Suzumiya J, Isobe Y, Oshimi K, Nakamura S, Suzuki R.

Cancer Sci. 2012 Jun;103(6):1079-83. doi: 10.1111/j.1349-7006.2012.02251.x. Epub 2012 Mar 23.

9.

Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study.

Yamaguchi M, Kwong YL, Kim WS, Maeda Y, Hashimoto C, Suh C, Izutsu K, Ishida F, Isobe Y, Sueoka E, Suzumiya J, Kodama T, Kimura H, Hyo R, Nakamura S, Oshimi K, Suzuki R.

J Clin Oncol. 2011 Nov 20;29(33):4410-6. doi: 10.1200/JCO.2011.35.6287. Epub 2011 Oct 11.

PMID:
21990393
10.

Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type.

Suzuki R, Yamaguchi M, Izutsu K, Yamamoto G, Takada K, Harabuchi Y, Isobe Y, Gomyo H, Koike T, Okamoto M, Hyo R, Suzumiya J, Nakamura S, Kawa K, Oshimi K; NK-cell Tumor Study Group.

Blood. 2011 Dec 1;118(23):6018-22. doi: 10.1182/blood-2011-05-354142. Epub 2011 Oct 7.

11.

Identification of Bcl-2/IgH fusion sequences using real-time PCR and chip-based microcapillary electrophoresis.

Tabe Y, Kawase Y, Miyake K, Satoh N, Aritaka N, Isobe Y, Oshimi K, Komatsu N, Miida T, Ohsaka A.

Clin Chem Lab Med. 2011 May;49(5):809-15. doi: 10.1515/CCLM.2011.141. Epub 2011 Feb 11.

PMID:
21309729
12.

Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system.

Tauchi T, Kizaki M, Okamoto S, Tanaka H, Tanimoto M, Inokuchi K, Murayama T, Saburi Y, Hino M, Tsudo M, Shimomura T, Isobe Y, Oshimi K, Dan K, Ohyashiki K, Ikeda Y; TARGET Investigators.

Leuk Res. 2011 May;35(5):585-90. doi: 10.1016/j.leukres.2010.10.027. Epub 2010 Dec 10.

PMID:
21145591
13.

Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.

Kojima M, Sato E, Oshimi K, Murase T, Koike T, Tsunoda S, Matsumoto T, Marutsuka K, Ogiya D, Moriuchi M, Tokunaka M, Yara Kikuti Y, Kikuchi T, Nakamura N, Ando K.

J Clin Exp Hematop. 2010;50(2):107-12.

14.

Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior.

Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, Hirano T, Komatsu N, Sugimoto K.

Leuk Lymphoma. 2010 Dec;51(12):2230-9. doi: 10.3109/10428194.2010.527403. Epub 2010 Nov 11.

PMID:
21067444
15.

Lymphomatoid gastropathy: a distinct clinicopathologic entity of self-limited pseudomalignant NK-cell proliferation.

Takeuchi K, Yokoyama M, Ishizawa S, Terui Y, Nomura K, Marutsuka K, Nunomura M, Fukushima N, Yagyuu T, Nakamine H, Akiyama F, Hoshi K, Matsue K, Hatake K, Oshimi K.

Blood. 2010 Dec 16;116(25):5631-7. doi: 10.1182/blood-2010-06-290650. Epub 2010 Sep 9.

16.

Suppression of eIF4E expression by L-Asparaginase.

Suto H, Yasuda H, Isobe Y, Sasaki M, Imai H, Tsutsui M, Oshimi K, Komatsu N, Sugimoto K.

Acta Haematol. 2010;123(4):215-9. doi: 10.1159/000313362. Epub 2010 Apr 27. No abstract available.

PMID:
20424434
17.

Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l-asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study.

Tsukune Y, Isobe Y, Yasuda H, Shimizu S, Katsuoka Y, Hosone M, Oshimi K, Komatsu N, Sugimoto K.

Eur J Haematol. 2010 Apr;84(4):310-5. doi: 10.1111/j.1600-0609.2009.01395.x. Epub 2009 Dec 10.

PMID:
20015242
18.

Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma.

Tsutsui M, Yasuda H, Suto H, Imai H, Isobe Y, Sasaki M, Kojima Y, Oshimi K, Sugimoto K.

Int J Lab Hematol. 2010 Aug 1;32(4):419-26. doi: 10.1111/j.1751-553X.2009.01204.x. Epub 2009 Nov 24.

PMID:
19968719
19.

Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type.

Suzuki R, Suzumiya J, Yamaguchi M, Nakamura S, Kameoka J, Kojima H, Abe M, Kinoshita T, Yoshino T, Iwatsuki K, Kagami Y, Tsuzuki T, Kurokawa M, Ito K, Kawa K, Oshimi K; NK-cell Tumor Study Group.

Ann Oncol. 2010 May;21(5):1032-40. doi: 10.1093/annonc/mdp418. Epub 2009 Oct 22.

PMID:
19850638
20.

Arsenic trioxide in a hemodialytic patient with acute promyelocytic leukemia.

Yamamoto Y, Sasaki M, Oshimi K, Sugimoto K.

Acta Haematol. 2009;122(1):52-3. doi: 10.1159/000243724. Epub 2009 Oct 7. No abstract available.

PMID:
19816009

Supplemental Content

Loading ...
Support Center